Chamber and committees

Scottish Government officials are actively considering new opportunities in relation to innovative and flexible approaches to pricing, including exploring outcome based reimbursement and commercial payment agreements. This work will also consider some of the associated uncertainty about a medicine’s clinical and/or cost effectiveness. As the work progresses, Scottish Government will engage with a range of stakeholders who can provide expertise in this area. In the meantime, Patient Access Schemes (PAS) offer the opportunity for outcome-based payments for cancer medicines. The feasibility of linking outcomes with pricing relies on whether the outcome of interest is routinely collected and readily available for monitoring. In addition, at UK level, Scottish Government officials are working with the Accelerated Access Collaborative (AAC). The AAC programme of work for ATMP treatments, which include cancer medicines, includes a workstream that is focused on new payment and reimbursement models.